Who are Duration of Treatment: Z-Phase, 2 years.'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SINECATECHINS, PODOFILOX, POLIDEXIDE SULFATE, SUTILAINS, PF-07202954 Single Dose, Pf-07059013.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/duration-of-treatment-z-phase-2-years.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Duration of Treatment: Z-Phase, 2 years. — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Duration of Treatment: Z-Phase, 2 years. (Duration of Treatment: Z-Phase, 2 years.) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-inflammatory. Area: Rheumatology.

phase 3 Anti-inflammatory Unknown Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Duration of Treatment: Z-Phase, 2 years. (Duration of Treatment: Z-Phase, 2 years.) — Organon and Co. Z-Phase is a medication that targets the body's natural processes to reduce inflammation and slow disease progression.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Duration of Treatment: Z-Phase, 2 years. TARGET	Duration of Treatment: Z-Phase, 2 years.	Organon and Co	phase 3	Anti-inflammatory	Unknown
SINECATECHINS	SINECATECHINS		marketed	Polyphenols	Unknown	2006-01-01
PODOFILOX	PODOFILOX		marketed	Topical antiviral	Unknown	1990-01-01
POLIDEXIDE SULFATE	POLIDEXIDE SULFATE		marketed	Unknown	Unknown	1974-01-01
SUTILAINS	SUTILAINS		marketed	Unknown	Unknown	1969-01-01
PF-07202954 Single Dose	pf-07202954-single-dose	Pfizer	marketed	Unknown	Unknown
Pf-07059013	pf-07059013	Pfizer	marketed	Unknown	Unknown

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-10-02 — SINECATECHINS · 7858662 · Formulation · US

Sponsor landscape (Anti-inflammatory class)

A. Vogel AG · 1 drug in this class
Bausch & Lomb Incorporated · 1 drug in this class
Marie Hudson, MD · 1 drug in this class
Organon and Co · 1 drug in this class
Panacea Biotec Ltd · 1 drug in this class
Prof. Dr. Stephan Weidinger · 1 drug in this class
Salus Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Duration of Treatment: Z-Phase, 2 years. — Competitive Intelligence Brief. https://druglandscape.com/ci/duration-of-treatment-z-phase-2-years. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab